Overview A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors Status: Completed Trial end date: 2012-12-01 Target enrollment: Participant gender: Summary Primary objective is to evaluate the safety and PK of IMGN388 Phase: Phase 1 Details Lead Sponsor: ImmunoGen, Inc.